

Biocon Biologics Greece SINGLE MEMBER P.C.**BALANCE SHEET AS AT MARCH 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31,</u> <u>2025</u>	<u>March 31,</u> <u>2024</u>
ASSETS			
Non-current assets			
Right to use assets		150	204
Financial assets			
(i) Other financial assets	1	1	-
Deferred tax asset (net)		2,520	472
Total non-current assets		2,671	676
Current assets			
Inventories	2	2,644	3,036
Financial assets			
(i) Trade receivables	3	6,115	5,083
(ii) Cash and cash equivalents	4	341	91
Other current assets	5	73	37
Total current assets		9,173	8,247
TOTAL		11,844	8,923
EQUITY AND LIABILITIES			
Equity			
Equity share capital	6	-	-
Other equity	7	186	38
Total equity		186	38
Non-current liabilities			
Lease liabilities		98	150
Total current liabilities		98	150
Current liabilities			
Financial liabilities			
(i) Trade payables	8	9,200	7,852
(ii) Lease liabilities		56	56
Income-tax liability (net)		1,943	485
Provisions	9	22	8
Other current liabilities	10	339	334
Total current liabilities		11,560	8,735
TOTAL		11,844	8,923

Biocon Biologics Greece SINGLE MEMBER P.C.**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	Year ended March 31, 2025	Period ended March 31, 2024
Income			
Revenue from operations	11	9,802	2,285
Other operating income	12	1	-
Total revenue		9,803	2,285
Expenses			
Purchases of traded goods	13	7,119	4,582
Changes in inventories of traded goods	14	392	(3,036)
Employee benefits expense	15	1,118	342
Depreciation		53	9
Finance Costs	16	12	2
Other expenses	17	917	342
Total expenses		9,611	2,241
Profit before tax		192	44
Tax expense			
Current tax		2,549	483
Deferred Tax		(2,505)	(472)
Total tax expense		44	11
Profit for the year		148	33

Biocon Biologics Greece SINGLE MEMBER P.C.**STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2025	Period ended March 31, 2024
I Cash flows from operating activities		
Profit after tax	148	33
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Depreciation and amortisation (net)	53	9
Unrealised foreign exchange (gain)/loss	1	-
Finance costs	12	2
Tax expense	44	11
Operating profit before working capital changes	258	55
Movements in working capital		
(Increase) / Decrease in trade receivables	(1,032)	(4,539)
(Increase) / Decrease in trade inventories	392	(269)
(Increase) / Decrease in loans and advances and other assets	(37)	(37)
Increase / (Decrease) in trade payable, other liabilities and provisions	1,369	4,879
Cash generated generated / (used in) operations	950	89
Direct taxes paid	(634)	-
Net cash flow generated / (used in) from operating activities	316	89
II Cash flows from financing activities		
Repayment of lease liabilities	(64)	(8)
Net cash flow generated / (used) in financing activities	(64)	(8)
III Net increase in cash and cash equivalents (I + II)	252	81
IV Effect of exchange differences on cash and cash equivalents held in foreign currency	(1)	-
V Cash and cash equivalents at the beginning of the period	91	10
VI Cash and cash equivalents at the end of the period	341	91
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	341	91
Total cash and cash equivalents [Refer note 3]	341	91

Biocon Biologics Greece SINGLE MEMBER P.C.**Notes to financial statements for the year ended March 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2025	March 31, 2024
1. Other non-current financial assets		
Deposits	1	-
	1	-
2. Inventories		
Finished Goods	2,644	3,036
	2,644	3,036
3. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment		
Unsecured, considered good	6,115	5,083
	6,115	5,083
4. Cash and cash equivalents		
Balances with banks:		
On current accounts	341	91
	341	91
5. Other current assets		
Advance to suppliers	72	37
Prepayments	1	-
	73	37
6. Share capital		
Authorised		
Issued, subscribed and fully paid-up		
Equity share 1 Common stock of EUR 1 each	-	-
	-	-
7. Other equity		
Surplus/(deficit) in the statement of profit and loss		
Balance as per the last financial statements	38	-
Profit for the year	148	38
Net surplus in the statement of profit and loss	186	38
Total other equity	186	38
8. Trade payables	9,200	7,852
9. Provisions		
Current		
Compensated absences	22	8
	22	8
10. Other liabilities		
Current liabilities		
Statutory liabilities	215	334
Employee related payables	124	-
	339	334

Biocon Biologics Greece SINGLE MEMBER P.C.**Notes to financial statements for the year ended March 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2025	Period ended March 31, 2024
11. Revenue from operations		
Sale of Products		
Traded Goods	9,610	2,285
Sale of Services		
Support service cross charge to Group Companies	192	-
	9,802	2,285
12. Other operating income		
Foreign exchange fluctuations, net	1	-
	1	-
13. Purchase of traded goods	7,119	4,582
14. Changes in inventories of traded goods		
Inventory at the beginning of the year		
Traded goods	3,036	-
Inventory at the end of the year		
Traded goods	2,644	3,036
	392	(3,036)
15. Employee benefits expense		
Salaries, wages and bonus	1,084	342
Employee stock compensation expense	5	-
Staff welfare expenses	29	-
	1,118	342
16. Finance Costs		
Interest on lease obligation	12	2
	12	2
17. Other expenses		
Rates and taxes	3	
Rent	41	11
Distribution cost	222	31
Legal and professional fees	258	61
Repair and Maintenance	5	-
Travelling and conveyance	135	30
Sales promotion expenses	230	203
Freight outwards and clearing charges	(1)	-
Printing and stationery	4	3
Communication expenses	4	1
Miscellaneous expenses	16	2
	917	342